Under hypoxia, most of glucose is converted to secretory lactate, which leads to the lack of carbon source from glucose and thus the overuse of glutamine-carbon. However, under such a condition how glutamine nitrogen is disposed to avoid releasing potentially toxic ammonia remains to be determined. Here we identify a metabolic flux of glutamine to secretory dihydroorotate under hypoxia. We found that glutamine nitrogen is indispensable to nucleotide biosynthesis, but enriched in dihyroorotate and orotate rather than processing to its downstream uridine monophosphate under hypoxia. Dihyroorotate, not orotate, is then secreted out of cells. The specific metabolic pathway occurs in vivo and is required for tumor growth. Such a metabolic pathway renders glutamine mainly to acetyl coenzyme A for lipogenesis, with the rest carbon and nitrogen being safely removed. Our results reveal how glutamine carbon and nitrogen are coordinatively metabolized under hypoxia, and provide a comprehensive understanding on glutamine metabolism.
INTRODUCTION
Proliferating cancer cells comprehensively rewire their metabolism to sustain growth and survival in the harsh conditions, such as hypoxia and nutrition deficiency (1) . Upon the resurgence of research interest into cancer metabolism, aberrant glucose utilization has been centrally studied recently. As a famous hallmark of cancers, aerobic glycolysis, termed the Warburg effect, is characterized by the increased metabolic flux of glucose to secretory lactate (2) . This process leads to the lack of carbon source from glucose to make building bricks, especially lipids, for cell proliferation. Therefore, the alternative carbon source is required for cell growth. Second to glucose, glutamine, the most abundant amino acid in the human blood (3) , can serve as a ready source of carbon to support energy generation and biomass accumulation.
Glutamine plays a pleiotropic role in cellular functions (4) . Directly, glutamine can be incorporated to protein, and regulate protein translation and trafficking (5) . Through catabolic transformations, glutamine provides carbon and nitrogen for the biosynthesis of non-essential amino acids (5) and nucleotides (6, 7) . In addition, glutamine can also forward fuel the citric acid cycle (CAC) (8, 9) . Under hypoxia, the glutamine consumption in proliferating cells is elevated, and it preferentially provides carbon for fatty acid biosynthesis through reductive carboxylation (10) , by which glutamine-derived α-ketoglutarate is reduced to citric acid by isocitrate dehydrogenases with NADPH oxidizing to NADP + .
One glutamine contains five carbon atoms and two nitrogen atoms in the forms of amine and amide groups. When cells begin to addict to glutamine carbon, which usually happens on proliferating cancer cells under hypoxia (4), how do they deal with the potentially overflowed nitrogen? It has long been supposed that glutamine offers α-ketoglutarate for cells by deamination through glutaminase (GLS) (11) and glutamate dehydrogenase (GLUD) (9) .
Concomitantly with these processes, the increasing amount of ammonia is produced and could be toxic to cells (12, 13) . Although a recent report showed that breast cancer cells could slightly recycle ammonia to generate amino acids through GLUD (14) , GLUD-mediated conversion of ammonia and α-ketoglutarate to glutamate does not efficiently occur in most of cancer cells (4, 15) . The best way for proliferating cancer cells is to reduce the generation of potentially toxic ammonia. Therefore, how glutamine nitrogen is coordinatively metabolized to avoid releasing ammonia deserves to be further determined.
Different elements in a metabolite usually have different metabolic fates, thus their coordinative metabolism is critical to maintain the metabolic homeostasis in cells. Once the changed microenvironment perturbs the homeostasis, re-building a new coordinative metabolism is required. Here we show that hypoxia alters glutamine metabolism and drives a new metabolic homeostasis of its carbon and nitrogen.
RESULTS

Requirement of Glutamine-Nitrogen for Cell Survival.
Glutamine is required for cell survival (16) (17) (18) (19) , and its loss induced cell death ( Fig. 1A ; Supplementary Fig. S1A ). Supplementation with nucleosides, but not α-ketoglutarate and non-essential amino acids including glutamate, significantly suppressed cell death in MCF-7, HeLa and A549 cells induced by glutamine loss ( Fig. 1A; Supplementary Fig. S1A and S1B), supporting the well-established notion that glutamine is necessary for nucleotide biosynthesis (6) . In fact, glutamine can be potentially synthesized from glutamate by glutamine synthetase (GS) (Fig. 1B) . However, glutamine deprivation led to a dramatic loss of cellular glutamine (about 5% of the control) but showed no or less effect on other non-essential amino acids and the intermediates in the CAC in MCF-7 and HeLa cells ( Fig.   1C ; Supplementary Fig. S2A-S2C ). Notably, the culture medium did not contain non-essential amino acids including glutamate. It suggests that cells could synthesize glutamate from α-ketoglutarate ( Fig. 1B) . We then used the labeled carbon source, 13 C 6 -glucose, to culture MCF-7 and HeLa cells, and the 13 C tracing analysis showed that α-ketoglutarate and glutamate were substantially labeled by 13 C even in the presence of glutamine but the glucose-derived fraction significantly increased in the absence of glutamine ( Fig. 1D ; Supplementary Fig. S2D-S2F ). Nonetheless, glutamine was not labeled at all in the presence of glutamine but slightly labeled, when compared to α-ketoglutarate and glutamate, in the absence of glutamine ( Fig. 1D and 1E ; Supplementary Fig. S2D-S2G ). These results suggest that glutamine cannot be efficiently synthesized in cells even upon its scarcity, and it could be attributed to the low level of GS. We then over-expressed GS in MCF-7 cells (Fig. 1F ), and found it dramatically increased the labeling of glutamine, but not glutamate and α-ketoglutarate, by 13 C 6 -glucose ( Fig. 1G and 1H ; Supplementary Fig. S2H ). GS expression also inhibited cell death and restored cell proliferation upon supplementation with glutamate, α-ketoglutarate or pyruvate in MCF-7, HeLa and A549 cells in the absence of glutamine ( Fig.   1I ). Conversely, GS knockdown sensitized cells to glutamine loss independently of supplementation of nutrients (Fig. S2I) . These data suggest that glutamine amide-nitrogen is indispensable to cell proliferation. When glutamine nitrogen is used, its carbon, if beyond biomass accumulation, could be oxidized via the citric acid cycle. However, when the cellular requirement of glutamine carbon is increased in some conditions, such as under hypoxia, how do cells metabolically dispose of the overflowed nitrogen?
Increased Uptake of Glutamine and Decreased Production of Ammonia Under Hypoxia
Under hypoxia, glutamine was used as the major carbon source, especially for lipid biosynthesis ( Fig. 2A ) (10) . Indeed, we detected a significantly increased uptake of glutamine but decreased excretion of glutamate in both MCF-7 and HeLa cells ( Fig. 2A-2C ). We then traced the metabolic flux of U-13 C-labeled glutamine. Consistent with the previous report (10), the fraction of glutamine-derived acetyl-CoA m+2, the precursor of lipogenesis, was significantly enhanced (Fig. 2D ). In addition, the increased enrichment of glutamine-13 C in glutamate, proline, α-ketoglutarate and citrate, downstream metabolites of glutamine, was also detected ( Fig. 2E and 2F ; Supplementary Fig. S3A-S3D ). These data suggest the increased uptake of glutamine as the carbon source under hypoxia. Next, we tried to figure out the metabolic fate of glutamine nitrogen under hypoxia. Glutamine can be deaminated and release its nitrogen as ammonia (4) ( Fig. 2A ), thus we measured the ammonia in the culture medium. As showed in Fig. 2G , the production of ammonia was actually significantly decreased. Ammonia can be removed by forming urea in human body (20, 21) , and we did not detect urea in the culture medium but measured a decreased level of intracellular urea ( Fig.   2H ). In addition, we also detected a decreased excretion of alanine, the potential ammonia carrier (21) , in the medium (Fig. 2I ). Therefore, glutamine-nitrogen should be enriched in some other cellular metabolites under hypoxia.
Accumulation of Cellular Nucleotide Precursors Under Hypoxia
We then used HeLa and 4T1 cell lines as the models to screen the nitrogen metabolome including 226 nitrogen-contained metabolites. Hypoxia significantly (P < 0.05) increased six and decreased eleven overlapped metabolites in both HeLa and 4T1 cells (Fig. 3A ).
Interestingly, five increased compounds, including dihydroorotate, orotate, IMP, guanosine and inosine, were involved in the nucleotide biosynthesis pathway ( Fig. 3B ). We verified again that IMP, the precursor of AMP and GMP, significantly enhanced and carbamoyl-Asp, dihydroorotate and orotate, the precursors of UMP, dramatically increased in HeLa, MCF-7 and 4T1 cells under hypoxia ( Fig. 3C and 3D ). Furthermore, we measured the cellular nucleotides and their derivatives in HeLa and MCF-7 cells under hypoxia. As shown in Fig.   3E , only the cellular GMP raised upon hypoxia. On the contrary, UMP and its derivatives, UDP, UTP and CTP, even reduced under hypoxia ( Fig. 3E) , which was also supported by the metabolomic profiling that UTP and thymidine triphosphate (dTTP), the other UMP derivative, were observed to decrease in the hypoxic cells ( Fig. 3A) .
Surprisingly, the metabolomic analysis showed that aspartate, the major precursor for carbamoyl-Asp, dihydroorotate and orotate ( Fig. 3B ), significantly declined under hypoxia ( Fig. 3A) , which was confirmed again in MCF-7, HeLa and 4T1 cells ( Fig. 3D ). We further measured the levels of cellular amino acids in MCF-7 and HeLa cells under hypoxia and normoxia. We observed the increased cellular glutamine and glutamate in both cell lines under hypoxia ( Fig. 4A ), which should result from the increased uptake of glutamine ( Fig.   2B ). Intriguingly, our results in MCF-7 and HeLa cells clearly indicated that only aspartate significantly decreased in both cell lines ( Fig. 4A ). This could explain why accumulated IMP ( Fig. 3C ) led to an increase in GMP but not in AMP ( Fig. 3E ), because the conversion of IMP to AMP required aspartate participation ( Fig. 3B ).
Taken together, these data indicate that hypoxia substantially lead to the accumulation of cellular nucleotide precursors, in particular pyrimidine precursors including carbamoyl-Asp, dihydroorotate and orotate.
Promotion of Glutamine-Derived Aspartate to Pyrimidine Precursors Under Hypoxia
Given that the cellular level of aspartate significantly decreased while those of the downstream carbamoyl-Asp, dihydroorotate and orotate dramatically increased ( Fig. 3D ), aspartate is possibly largely promoted by hypoxia to its downstream products.
We next investigated whether and how glutamine-derived aspartate was assimilated into pyrimidine precursors under hypoxia by tracing the metabolic flux of 13 C 5 -labeled glutamine.
Glutamine carbon can be potentially integrated into pyrimidine nucleotides through the CAC-mediated oxidative pathway or α-ketoglutarate carboxylation reductive pathway (Fig.   4B ). The two pathways can be distinguished by determining the enrichment of 13 C 5 -glutamine-derived 13 4C ) and citrate m+5 ( Supplementary Fig. S3A and S3B), dihydroorotate m+3 and orotate m+3 ( Fig. 4D and 4E) were generated via the reductive pathway. Finally, UMP m+3 was produced in both pathways ( Supplementary Fig. S3A and S3B). These results clearly showed that glutamine carbon was integrated into acetyl-CoA (the precursor for lipid biosynthesis) and aspartate-derived dihydroorotate and orotate through the reductive pathway under hypoxia. Moreover, the fraction of glutamine-13 C-labled acetyl-CoA, dihydroorotate and orotate significantly increased ( Fig. 2D and 4F ). These data suggest that the biosyntheses of acetyl-CoA, dihydroorotate and orotate from glutamine were urged by hypoxia. However, aspartate, the direct precursor of dihydroorotate, was less efficiently labeled by glutamine- 13 C under hypoxia ( Fig. 3F ). This most likely resulted from the compartmental biosynthesis of cellular aspartate. Aspartate can be synthesized in the cytoplasm and mitochondria respectively by cytosolic glutamic-oxaloacetic transaminase 1 (GOT1) and mitochondrial glutamic-oxaloacetic transaminase 2 (GOT2) (4), while dihydroorotate or orotate is produced in the cytoplasm. When the glutamine-derived cytosolic aspartate m+3 is largely converted to dihydroorotate and orotate, it could be diluted by the unlabeled mitochondrial aspartate due to its decreased level. These data support that hypoxia strongly boosts enter of glutamine-derived aspartate to dihydroorotate and orotate.
Glutamine-Nitrogen is Enriched in Excretory Dihydroorotate Under Hypoxia
Now we asked whether amino acids assimilated more glutamine-nitrogen under hypoxia.
We cultured HeLa and MCF-7 cells with amide-15 N-labeled or amine-15 N-labeled glutamine, and then traced the 15 N-labeled amino acids. Our results showed that glutamine-amine-15 N labeled non-essential amino acids, such glutamate, proline, asparagine, aspartate and alanine ( Fig. 5A ; Supplementary Fig. S4 ). In contrast, glutamine-amide- 15 N predominantly labeled asparagine in both MCF-7 and HeLa cells ( Fig. 5B ; Supplementary Fig. S5 ). In addition, glutamine-amide-15 N also slightly labeled non-essential amino acids in MCF-7 breast cancer cells, consistent with a recent report showing that breast cancer cells could metabolically recycle ammonia released from glutamine-amide nitrogen (14) . However, almost all the 15 N-labeled fraction of amino acids decreased under hypoxia ( Fig. 5A and 5B ). These data suggest that glutamine nitrogen is not enriched in amino acid under hypoxia.
Glutamine amine-15 N can be assimilated into both purine and pyrimidine nucleotides with one 15 N atom (m+1) in aspartate, dihydroorotate, orotate, UMP and IMP (the precursor of purine nucleotides) ( Fig. 4B ; Supplementary Fig. S6 ). In contrast, glutamine amide-15 N labeled dihydroorotate, orotate and UMP with one 15 N atom (m+1) and IMP with two 15 N atoms (m+2) ( Fig. 4B ; Supplementary Fig. S7 ). The labeling pattern did not change under hypoxia ( Fig. 4B ), but labeled fractions of dihydroorotate and orotate significantly increased under hypoxia ( Fig. 5C and 5D ), suggesting an increased metabolic flux of glutamine-nitrogen to dihydroorotate and orotate under hypoxia. However, dihydroorotate and orotate inefficiently processed to its downstream UMP, because cellular UMP did not increase ( Fig. 3D ) and less labeled by glutamine-13 C and -15 N (Fig. 4F , 5C and 5D). In addition to UMP, IMP also showed reduced labeled fractions under hypoxia ( Fig. 5C and 5D ), which possibly resulted from the slowed cell proliferation rate. Supplementary Fig. S8 ), which could remit hypoxia-induced electron accumulation. The reprogrammed metabolic pathway essentially renders glutamine only to acetyl-CoA for lipogenesis under hypoxia.
To confirm whether the enrichment of glutamine-nitrogen in dihydroorotate is associated with its carbon metabolism, we treated HeLa cells with α-ketoglutarate, the carbon form of glutamine. Our results showed that α-ketoglutarate supplementation almost completely scavenged the accumulated cellular dihydroorotate and orotate ( Fig. 5G and 5H ), suppressed the excretion of dihydroorotate ( Fig. 5I ), and meantime significantly reversed cellular aspartate under hypoxia ( Fig. 5J ). These data clearly suggest that the increased biosynthesis and excretion of dihydroorotate is attached to the metabolism of glutamine-carbon.
Hypoxia-Induced Electron Accumulation Promotes Biosynthesis and Excretion of
Dihydroorotate
Next, we investigated how hypoxia promoted the biosynthesis and excretion of dihydroorotate. We measured the protein levels of related enzymes, including GOT1, carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD), dihydroorotate dehydrogenase (DHODH) and uridine monophosphate synthetase (UMPS) ( Fig. 5E ), as well as HIF-1α. As a typical indicator, HIF-1α was indeed induced by hypoxia, but the expression of these metabolic enzymes were not enhanced ( Fig. 6A ). CAD is the critical enzyme for the biosynthesis of dihydroorotate, and can be activated by phosphorylation (22, 23) . The level of phosphorylated CAD was increase in MCF-7 cells but decreased in HeLa cells under hypoxia ( Fig. 6A ). These inconsistent data suggest that the hyper-biosynthesis of dihydroorotate most likely is not mediated by hypoxia-regulated protein levels.
Hypoxia also disabled the mitochondrial electron transport chain (ETC) and induced the accumulation of electrons, such as NADH ( Fig. 6B ). Interestingly, mitochondrial dysfunction was previously reported to promote cells to use glutamine-carbon for acetyl-CoA through the reductive pathway (24) . Here, we confirmed that the inhibition of the electron transport chain by antimycin A induced NADH accumulation ( Fig. 6B ) and push glutamine-carbon into acetyl-CoA in HeLa, MCF-7 and 4T1 cells ( Fig. 6C ), but it did not induce HIF-1α ( Fig. 6D ).
We then used HeLa and 4T1 cells to perform a targeted metabolomic analysis. Eighteen overlapped nitrogen-contained metabolites in both HeLa and 4T1 cells were significantly affected by antimycin A ( Fig. 6E ; Supplementary Fig. S9A ), among which 8 overlapped metabolites, including increased dihydroorotate and decreased aspartate and UTP, were also found to be significantly changed by hypoxia ( Fig. 3A and 6E ; Supplementary Fig. S9A ). In fact, the level of cellular aspartate was also previously observed to reduce in cells with the ETC dysfunction (25, 26) . The tracing analysis showed that antimycin A, similar to hypoxia, also promoted metabolic flux of 13 C 5 -glutamine to aspartate m+3 and dihydroorotate m+3 through the reductive pathway ( Supplementary Fig. S9B-S9D ). Importantly, the excretion of dihydroorotate, not orotate, was detected in the culture medium with antimcyin A treatment ( Fig. 6F ). Now, we tried to alleviate the electron accumulation in HeLa cells under hypoxia using a pyruvate analogue, α-ketobutyrate that can be reduced to excretory α-hydroxybutyrate by NADH-consuming lactate dehydrogenases and thus neutralize NADH accumulation (25) . Our results showed that supplementation of α-ketobutyrate indeed decreased NADH/NAD + ratio ( Fig. 6G ). Meantime, we also observed that α-ketobutyrate attenuated excretory dihydroorotate ( Fig. 6H ), glutamine-derived acetyl-CoA m+2 ( Fig. 6I ), cellular dihydroorotate ( Fig. 6J ) and orotate (Fig. 6K ), and restored cellular aspartate ( Fig. 6L ). Taken together, these data suggest that hypoxia-induced NADH accumulation promotes the biosynthesis and excretion of dihydroorotate. NADH acts as the coenzyme of many cellular transformations, and thus its accumulation could extensively influence these reactions and reprogram cellular metabolism. NADH accumulation most likely indirectly activates CAD while suppresses UMP, given that the two enzymes do not directly employ NADH/NAD + .
Increased Dihydroorotate Biosynthesis is Required for in vivo Tumor Growth
In view of the in vivo hypoxic microenvironment of tumors, we then measured the blood dihydroorotate and orotate in patients of breast cancer, lung cancer, gastric cancer and liver cancer, as well as healthy persons. However, cancer patients' blood orotate, but not dihydroorotate, was detected to significantly enhance compared to the healthy controls ( Fig.   7A and 7B). Furthermore, we measured the levels of blood dihydroorotate and orotate in healthy or HeLa-derived tumor-bearing nude mice, and both metabolites were found to significantly increase ( Fig. 7C and 7D ). To further investigate whether orotate was directly released from tumor or oxidized from dihydroorotate in blood, we administrated mice with intraperitoneal injection with amide-15 N-labeled glutamine ( Supplementary Fig. S10A ).
Dihydroorotate and orotate in the tumor tissue was rapidly labeled by 15 N ( Supplementary Fig.   S10B ). About 35% and 25% of blood dihydroorotate was labeled by 15 N at 1h and 2h postinjection in tumor-bearing but not in healthy mice ( Fig. 7E ; Supplementary Fig. S10C and S10D). In contrast, only less than 10% of blood orotate was labeled in these mice, and a slightly increased labeled fraction of blood orotate was observed in tumor-bearing mice ( Fig.   7F ; Supplementary Fig. S10C and S10D). Similar results were also obtained from 4T1-derived tumor-bearing mice ( Supplementary Fig. S10E -S10H). These data suggest that the in vivo tumors could directly excrete dihydroorotate that is somehow rapidly converted to orotate in blood ( Fig. 7G ). The amount of blood orotate was much greater than that of blood dihydroorotate in mice ( Fig. 7C and 7D ; Supplementary Fig. S10E and S10F), so that the newly synthesized 15 N-labeled orotate derived from dihydroorotate was largely diluted.
To test whether the increased metabolic flux of glutamine to dihydroorotate is required for cell survival under hypoxia, we knockdowned the involved enzymes, such as GOT1, CAD and DHODH in MCF-7 and HeLa cells ( Fig. 5E ). DHODH and CAD were the key enzymes involved in the biosynthesis of pyrimidine nucleotides, thus knockdown of DHODH and CAD apparently suppressed proliferation of these cells even in the normal condition ( Fig. 7I ).
In contrast, GOT1 knockdown slightly affected cell proliferation ( Fig. 7I ). However, knockdown of CAD or GOT1 strongly, while DHODH knockdown marginally, sensitized cancer cells to hypoxia ( Fig. 7I ). CAD appeared to be required for robust cell growth in both normoxic and hypoxic conditions, and thus could be important for tumor progression. The speculation was confirmed by the animal experiments that CAD knockdown suppressed the in vivo tumor growth much more significantly than knockdown of DHODH or GOT1 ( Fig. 7J ).
Furthermore, higher levels of CAD showed a positive correlation with a shorter overall survival time in patients of breast cancer, lung cancer, gastric cancer and liver cancer ( Supplementary Fig. S11 ). These data suggest that the increased biosynthesis of dihydoorotate from glutamine is critical for the in vivo tumor growth.
DISCUSSION
In this study, we reveal a specific metabolic pathway that hypoxia pushes glutamine carbon and nitrogen via the reductive pathway to dihydroorotate that are then expelled outside of cells rather than processing to their downstream UMP. This unique metabolic reprogramming probably has a vital physiological relevance. Proliferating cancer cells require glutamine carbon to generate acetyl-CoA for lipid synthesis under hypoxia. During this process, cells need to properly dispose of the concomitant "by-products", nitrogen (ammonia/ammonium) and oxaloacetate that could not be effectively catabolized under hypoxia, from glutamine. The accumulation of these "by-products", particularly ammonia, could be toxic to cells (12, 13, 21) . The secretion of dihydroorotate perfectly scavenges both the rest nitrogen and carbon and renders glutamine mainly to acetyl-CoA in cells.
The amide nitrogen of glutamine is most often used to synthesize asparagine and nucleotide, concomitantly with production of glutamate (27) . Glutamate can be used for multiple purposes, but it can be readily synthesized through the transamination between α-ketoglutarate and other amino acids, thus it is dispensable to cancer cell proliferation. By contrast, the biosynthesis of glutamine from glutamate is inactive in cancer cells ( Fig. 1D and   1E ). Therefore, the amide-nitrogen of glutamine is necessary to cell growth. Normally, when the amide-nitrogen of glutamine is used, the resultant glutamate, if beyond the metabolic requirement, could be excreted out of cells or replenish the citric acid cycle after its transamination. Once the metabolic assimilation of glutamine amide-nitrogen could not keep pace with that of glutamine carbon, cells need to get rid of the superfluous amide-nitrogen.
Generally, glutamine is thought to liberate amide-nitrogen as ammonia and converted to glutamate that can further produce α-ketoglutarate upon either deamination or transamination (5, 9, 11) . The accumulated ammonia is potentially toxic to cells and should be safely removed. In mammalian cells, there are three enzymes accounting for ammonia assimilation (28, 29) . GS synthesizes glutamine from glutamate and ammonia, and this process is essentially a reversion of glutamine deamination and thus does not play a real role in scavenging glutamine-derived ammonia. Carbamoyl phosphate synthetase I (CPSI) incorporates ammonia to urea, but we detected a decreased cellular level in cancer cells under hypoxia ( Fig. 2H ). GLUD can convert α-ketoglutarate and ammonia to glutamate whose amine group could be further transferred to other amino acids. Unfortunately, GLUD-mediated ammonia assimilation inefficiently or does not take place in cancer cells (4, 15) , especially in the hypoxic condition ( Fig. 5B ). Therefore, proliferating cancer cells develop the specific metabolic pathway to dispose of glutamine amide-nitrogen. Dihydroorotate is somehow rapidly converted to orotate in the blood, as suggested in our current study ( Fig. 7G ). As a fact, urea cycle disorders can also lead to orotic aciduria, a symptom of an increased urinary orotate (32, 33) , supporting that the excretion of dihydoorotate/orotate is an alternative pathway to dispose of the toxic ammonia. Due to the in vivo hypoxic microenvironment around tumor cells, we indeed measure the increased level of blood dihydroorotate/orotate in cancer patients or tumor-bearing mice. It suggests that the specific metabolic flux of glutamine to excretory dihydroorotate/orotate exists in vivo.
Therefore, the blood dihydroorotate/orotate may be a potential biomarker for cancer diagnosis, and the involved metabolic enzymes, such as CAD and GOT1, could be potential targets for cancer treatments.
METHODS
Cell Culture
MCF-7, A549, HeLa, HCC-LM3, SGC-7901 and 4T1 cells were obtained from ATCC. All the cells were maintained in high glucose DMEM supplemented with 10% fetal bovine serum (BioInd, Israel) and 50 IU penicillin/streptomycin (Invitrogen, USA) in a humidified atmosphere with 5% CO 2 at 37℃. Hypoxia studies were carried out at 1% oxygen.
Cell Imaging and Cell Death Assay
10×10 4 cells expressing GC3AI were grown in 12-well plates, and after the desired treatments, cells were then rapidly imaged with an EVOS® FL digital inverted fluorescence microscope with 10× objective lens. The filter sets for imaging were: GFP: Ex470/22, Em525/50. Cell death assay was performed as previous (34, 35) , GFP-positive cells were counted as apoptosis. Five random areas in each well were imaged, and each area contained more than one hundred of cells. Cell counting was performed with ImageJ software (1.47) by analyzing these pictures.
Proliferation Assay
Cells were plated in triplicate in 12-well plates at 5×10 4 cells per well in 1.5 ml. After days as indicated in experiments, wells were washed twice with PBS buffer to remove dead cells, and then the entire contents of the well were trypsinized. Cell number was determined using a hemocytometer. For each well, the fold change in cell number relative to Day 0 was presented in a log 2 scale. For metabolite profiling experiments, cells were grown in 60-mm dishes until 80% confluent, then rinsed with PBS and cultured with 2 ml DMEM containing 10% dialyzed FBS for 8h under normoxia or hypoxia or in the presence of 1 μM antimycin A. To determine the relative abundance of intracellular metabolites across samples, cells was extracted with 0.5 ml 80% pre-chilled methanol. Samples were prepared and analyzed as described in the above.
NADH/NAD + Ratio Assay
The areas of the ion peaks of interest were corrected by cell number. Finally, the relative abundance of metabolites was compared with each other.
Targeted Metabolomics
HeLa and 4T1 cells were grown in 60-mm dishes until 80% confluent, then cultured under hypoxia (1% O2) or treated with antimycin A (1 μM) for 8h. Samples were prepared as described in the section of "Metabolite Profiling and Isotope Tracing". Samples were randomized, in order to avoid machine drift, and were blinded to the operator. 
Metabolite Uptake and Excretion
Levels of analine, glutamate, glutamine, orotate and dihydroorotate were determined using LC/MS. Conditioned medium was sampled after 8 hr. 100 μl medium was extracted with 400 μl 100% pre-chilled methanol with 10 ng/ml 15 N 2 -orotate as the internal standard.
The mixture was centrifuged at 14,000g for 20 min at 4-8 ℃, and the metabolite-containing supernatants were dried under nitrogen gas. Dried samples were stored at -80 ℃ and then resuspended in 50 μl 80% methanol and prepared for LC/MS analyses as described in the section of "Metabolite Profiling and Isotope Tracing". The amount of orotate can be directly calculated by comparing the area of the ion peak of orotate to that of internal 15 N 2 -orotate.
Since no available dihydroorotate isotope was used as the internal standard, medium dihydroorotate could not be directly quantified. Therefore, 100 μl aliquots of control medium 
The unit for R is mol/(cell·hr) or mol/cell/hr. 
S = f(t)·dt
t 1 0 = N initial · t 1 · ln(N final /N initial0 ) ( e -1) ln(N final /N initial ) t t 1 0 N initial
Animal Experiments
The animal protocol was approved by the Institute Animal Care and Use Committee at Tianjin Medical University, in accordance with the principles and procedures outlined in the NIH Guide for the Care and Use of Laboratory Animals. Female nude mice (4-5 weeks,
19-20 g) were purchased from the Experimental Animal Center of Nanjing Biomedical
Research Institute at Nanjing University. Mice were administered with a standard, housed and maintained in pathogen-free house in a 12:12 h light-dark cycle. Temperature and humidity were maintained at 24 ± 2 °C and 50 ± 5%, respectively. 5x10 6 cells of HeLa/shScramble, HeLa/shDHODH#1, HeLa/shCAD#1 or HeLa/shGOT1#1 were injected subcutaneously into the groins of 5-week-old mice, and 5 mice were used for each cell line. After establishment of palpable tumors, tumor growth was measured every three days using digital calipers, and volumes were calculated using the formula 1/2 x L x W 2 . All of the mice were killed at the end and tumors were harvested and weighed.
For in vivo tracing studies, when HeLa/wt-derived tumors reached about 500 mm 3 , six tumor-bearing mice，as well as six healthy mice, were injected with amide- 15 
Gene Construction and Lentivirus Production
All cDNAs were cloned into lentiviral expression vectors, pCDH-puro-CMV or pCDH-Neo-CMV. The pLKO.1 lentiviral RNAi expression system was used to construct lentiviral shRNA for genes. The sequences of shRNA used in this study included the following:
shScramble: CCTAAGGTTAAGTCGCCCTCG, shDHODH-#1:
GTGAGAGTTCTGGGCCATAAA, shDHODH-#2: CGATGGGCTGATTGTTACGAA, shGOT1-#1: GCGTTGGTACAATGGAACAAA, shGOT1-#2:
GCTAATGACAATAGCCTAAAT, shCAD-#1: CGAATCCAGAAGGAACGATTT, shCAD-#2: GCTCCGAAAGATGGGATATAA. Viral packaging was done according to a previously described protocol. Briefly, expression plasmids pCDH-CMV-cDNA, pCMV-dR8.91, and pCMV-VSV-G were co-transfected into 293T cells using the calcium phosphate coprecipitation at 20:10:10 μg (for a 10-cm dish). The transfection medium containing calcium phosphate and plasmid mixture was replaced with fresh complete medium after incubation for 5 h. Media containing virus was collected 48 h after transfection and then concentrated using Virus Concentrator Kit (Biophay, China). The virus was resuspended in the appropriate amount of complete growth medium and stored at -80℃. Cancer cells were infected with the viruses at the titer of 100% infection in the presence of polybrene (10 μg/ml) for 48 h, and then cells were selected with puromycin or neomycin.
Statistics
Data are given as means ± SD. Statistical analyses were performed using unpaired, two-tailed Student's t test for comparison between two groups. Asterisks in the figure indicated statistical significances (*P<0.05; **P<0.01).
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Overall Reactions
Detailed Reactions Figure S9 . Targeted metabolomics of cells treated with antimycin A. A, Heatmap of N-contained metabolites in HeLa and 4T1 cells significantly (n=4, p < 0.05) affected by antimycin A treatment for 8h. Cellular metabolites were measured by LC-MS-based metabolomics. Metabolites with green color were also covered by hypoxia in Figure 3A . 
